List of Egnyte Life Sciences Customers
Mountain View, 94043, CA,
United States
Since 2010, our global team of researchers has been studying Egnyte Life Sciences customers around the world, aggregating massive amounts of data points that form the basis of our forecast assumptions and perhaps the rise and fall of certain vendors and their products on a quarterly basis.
Each quarter our research team identifies companies that have purchased Egnyte Life Sciences for Content Management from public (Press Releases, Customer References, Testimonials, Case Studies and Success Stories) and proprietary sources, including the customer size, industry, location, implementation status, partner involvement, LOB Key Stakeholders and related IT decision-makers contact details.
Companies using Egnyte Life Sciences for Content Management include: Neuren Pharmaceuticals, a Australia based Life Sciences organisation with 30 employees and revenues of $132.0 million, BridgeBio, a United States based Life Sciences organisation with 390 employees and revenues of $78.0 million, Moma Therapeutics, a United States based Life Sciences organisation with 10 employees and revenues of $1.0 million and many others.
Contact us if you need a completed and verified list of companies using Egnyte Life Sciences, including the breakdown by industry (21 Verticals), Geography (Region, Country, State, City), Company Size (Revenue, Employees, Asset) and related IT Decision Makers, Key Stakeholders, business and technology executives responsible for the software purchases.
The Egnyte Life Sciences customer wins are being incorporated in our Enterprise Applications Buyer Insight and Technographics Customer Database which has over 100 data fields that detail company usage of software systems and their digital transformation initiatives. Apps Run The World wants to become your No. 1 technographic data source!
Apply Filters For Customers
| Logo | Customer | Industry | Empl. | Revenue | Country | Vendor | Application | Category | When | SI | Insight |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
BridgeBio | Life Sciences | 390 | $78M | United States | Egnyte | Egnyte Life Sciences | Content Management | 2024 | n/a |
In 2024 BridgeBio implemented Egnyte Life Sciences as a Content Management platform to centralize clinical, R&D and regulatory data across its network of hub and spoke subsidiaries and external CRO partners. The deployment targeted clinical and R&D content workflows and Part 11 GxP compliance, establishing the foundational Content Management controls needed for regulated document handling and controlled data exchange with partners.
Configuration work focused on compliance and governance capabilities within Egnyte Life Sciences, including centralized permissions models, system-level audit trails, and validated storage for regulated artifacts. The implementation emphasized clinical and R&D data management modules and automated audit logging consistent with Part 11 requirements, enabling documented evidence trails for regulatory review.
Operational scope covered BridgeBio corporate sites, hub and spoke subsidiaries, and CRO partners, with data migration processes designed to simplify CRO data onboarding and handoffs. The program completed a platform validation in three months in the United States, demonstrating the validation and qualification pathway for Egnyte Life Sciences in a regulated environment.
Governance changes included centralized access controls, role based permissioning, and structured audit review workflows to support regulatory readiness and CRO collaboration. The deployment delivered easier CRO data migration, reproducible audit trails, and tighter governance for clinical, R&D and regulatory functions without introducing new vendor or system names beyond Egnyte Life Sciences.
|
 |
Moma Therapeutics | Life Sciences | 10 | $1M | United States | Egnyte | Egnyte Life Sciences | Content Management | 2023 | Pliancy |
In 2023, Moma Therapeutics implemented Egnyte Life Sciences under the Content Management category to secure lab to cloud data flows and streamline collaboration with contract research organizations for R&D and clinical operations in the United States. The deployment targeted ingestion of data from lab instruments and external collaborator access, and the program reduced internal support tickets related to file sharing and access.
Configuration centered on secure external collaborator access, lab data governance, and instrument data ingestion pipelines rather than electronic quality management functionality. Egnyte Life Sciences was configured to apply access controls, role based provisioning, data classification and audit logging to scientific datasets and clinical trial artifacts. Workflows emphasized controlled sharing of raw and processed research files and orchestration of CRO collaboration without introducing eQMS modules.
The implementation was delivered with IT services partner Pliancy and operated across Moma Therapeutics research and clinical teams in the United States. Governance changes included standardized external user onboarding, policy driven sharing, and operational support adjustments that reduced support ticket volume after go live. Integrations focused on ingesting laboratory instrument outputs into the Content Management platform to centralize R&D data flows and enable secure file exchange with CROs.
|
 |
Neuren Pharmaceuticals | Life Sciences | 30 | $132M | Australia | Egnyte | Egnyte Life Sciences | Content Management | 2023 | n/a |
In 2023, Neuren Pharmaceuticals implemented Egnyte Life Sciences as a validated eQMS to meet 21 CFR Part 11 and GxP requirements. The deployment used Egnyte Life Sciences within the Content Management category to provision distinct domains for test, validated GxP workflows, and non GxP collaboration, separating compliance bound content from routine team collaboration.
Neuren completed a full eQMS deployment in 12 weeks, configuring document control, validation management, and training record workflows inside the validated GxP domain. Operational scope focused on Australia where the rollout achieved nearly 100% training compliance, with quality and regulatory teams using Egnyte Life Sciences for controlled documents, audit readiness, and formal governance around document approvals and training sign off.
|
Buyer Intent: Companies Evaluating Egnyte Life Sciences
Discover Software Buyers actively Evaluating Enterprise Applications
| Logo | Company | Industry | Employees | Revenue | Country | Evaluated | ||
|---|---|---|---|---|---|---|---|---|
| No data found | ||||||||